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Summary
 
Apoptosis is induced by different stimuli, among them triggering of the death receptor CD95,
staurosporine, and chemotherapeutic drugs. In all cases, apoptosis is mediated by caspases, al-
though it is unclear how these diverse apoptotic stimuli cause protease activation. Two regula-
tory pathways have been recently identified, but it remains unknown whether they are func-
tionally independent or linked to each other. One is mediated by recruitment of the proximal
regulator caspase-8 to the death receptor complex. The other pathway is controlled by the re-
lease of cytochrome c from mitochondria and the subsequent ATP-dependent activation of the
death regulator apoptotic protease-activating factor 1 (Apaf-1). Here, we report that both path-
ways can be dissected by depletion of intracellular ATP. Prevention of ATP production com-
pletely inhibited caspase activation and apoptosis in response to chemotherapeutic drugs and
staurosporine. Interestingly, caspase-8, whose function appeared to be restricted to death re-
ceptors, was also activated by these drugs under normal conditions, but not after ATP deple-
tion. In contrast, inhibition of ATP production did not affect caspase activation after triggering
of CD95. These results suggest that chemotherapeutic drug–induced caspase activation is en-
tirely controlled by a receptor-independent mitochondrial pathway, whereas CD95-induced
apoptosis can be regulated by a separate pathway not requiring Apaf-1 function.
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poptosis is a highly conserved process which can be
triggered by a broad range of physiological and patho-
logical conditions. Recent evidence suggests that most
proapoptotic stimuli induce the activation of a family of in-
tracellular cysteine proteases called caspases (1, 2). These
proteases are synthesized as inactive proenzymes which,
upon proteolytic cleavage at aspartate residues, form an ac-
tive complex composed of two heterodimeric subunits.
Caspases lead to the proteolysis of a number of cellular sub-
strates, a process which finally results in the apoptotic col-
lapse of the cell.
One of the best-defined apoptotic pathways is mediated
by the death receptor CD95 (APO-1/Fas; references 3–5).
Triggering of CD95 by its natural ligand CD95L or agonis-
tic antibodies induces the formation of a death-inducing
signaling complex (DISC) consisting of the adaptor protein
Fas-associated death domain protein (FADD [MORT-1])
and procaspase-8 (FADD-like IL-1
 
b
 
–converting enzyme
[FLICE, Mch5]) (6–9). DISC formation is mediated by
two homophilic protein interaction domains: FADD con-
tains a COOH-terminal death domain (DD), which cou-
ples to the DD of the intracellular part of CD95. FADD, in
addition, contains an NH
 
2
 
-terminal so-called death effector
domain (DED), which binds to one of the DEDs of
caspase-8. Further downstream, caspase-8 triggers the pro-
teolytic activation of other caspases and cleavage of cellular
substrates.
Furthermore, recent studies have shown that mitochon-
dria play an important role in the regulation of apoptosis.
An early event in this process is the translocation of cyto-
chrome c from mitochondria into the cytosol, which is in-
hibited by antiapoptotic proteins of the Bcl-2 family (10,
11). In the cytosol, cytochrome c interacts with apoptotic
protease-activating factor 1 (Apaf-1), the mammalian ho-
mologue of the 
 
Caenorhabditis elegans
 
 cell death regulator
Ced-4 (12–14). A second cofactor required for Apaf-1
function is dATP (15). Binding of these two components
presumably leads to a conformational change in Apaf-1 and
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exposes the so-called caspase recruitment domain (CARD).
This region serves as protein interface by binding to
caspases that have a similar domain at their NH
 
2
 
 terminus
(16). A CARD motif has been identified in caspase-1, -2,
and -9, and caspase-8 contains a long prodomain that may
exert a similar regulatory function.
A redistribution of cytochrome c into the cytosol is ob-
served in a variety of apoptotic conditions, such as CD95
ligation, or treatment of cells with staurosporine and che-
motherapeutic drugs (10, 11, 17–19). However, it is cur-
rently unclear whether the mitochondria-controlled path-
way functions independently or is interconnected and
required for the CD95 pathway. It has been recently pro-
posed that anticancer drug–induced apoptosis occurs through
the CD95 pathway (20, 21). A variety of drugs have been
observed to induce upregulation of CD95L expression, fol-
lowed by the subsequent induction of CD95-dependent
apoptosis. However, there are also reports indicating that
antitumor drugs induce apoptosis in the absence of CD95
engagement (22–24).
In this study, we dissected the regulation of caspase acti-
vation in response to CD95 ligation and treatment of cells
with chemotherapeutic drugs. We demonstrate that, similar to
CD95, chemotherapeutic drugs are able to induce activa-
tion of the initiator caspase-8 and the effector caspase-3, yet
drug-induced caspase activation did not require the CD95
receptor/ligand system. We also investigated the contribu-
tion of the mitochondria/Apaf-1 pathway to apoptosis in-
duced by CD95, anticancer drugs, and staurosporine. For
this purpose, cells were depleted of ATP, which is required
for Apaf-1 function and mitochondria-controlled apoptosis.
We show that inhibition of ATP production completely
abolished caspase activation after treatment of cells with
staurosporine and anticancer drugs. In contrast, regardless
of ATP depletion, CD95-induced caspase activation was
not markedly affected. Our data suggest that drug-induced
caspase activation is independent of CD95 and involves
only the Apaf-1–regulated pathway, whereas CD95-medi-
ated apoptosis does not essentially require mitochondria-
controlled processes.
 
Materials and Methods
 
Cells and Reagents.
 
The human Jurkat T cell line was main-
tained in RPMI 1640 medium supplemented with 10% FCS, 10
mM Hepes, and antibiotics (all from GIBCO BRL, Eggenstein,
Germany). The CD95-resistant Jurkat subline Jurkat-R was gen-
erated by continuous culture in the presence of anti-CD95 mAb
(IgG
 
3
 
, 1 
 
m
 
g/ml; Cell Diagnostica, Münster, Germany) for 6 mo.
Etoposide and mitomycin C were obtained from the clinical
pharmacy (Medical Clinics, Tübingen, Germany). Doxorubicin,
cycloheximide, and oligomycin were purchased from Sigma (Deis-
enhofen, Germany) and staurosporine from Boehringer Mann-
heim GmbH (Mannheim, Germany). Mitomycin C was dissolved
in methanol, and doxorubicin, etoposide, and staurosporine in
ethanol and kept as stock solutions at 
 
2
 
70
 
8
 
C. Intracellular ATP
was depleted by incubating cells in glucose-free RPMI 1640 me-
dium supplemented with 2 mM pyruvate, 0.1% FCS, and 2.5
 
m
 
M oligomycin, an inhibitor of F
 
0
 
F
 
1
 
-ATPases, in order to pre-
vent production of ATP from both glycolysis and oxidative phos-
phorylation (25, 26).
 
Cell Extracts and Immunoblotting.
 
Cleavage of caspases and the
caspase substrate poly(ADP-ribose)polymerase (PARP) was de-
tected by immunoblotting. 2 
 
3
 
 10
 
6
 
 cells were seeded in 24-well
plates and treated with the apoptotic stimuli. After the indicated
time periods, cells were washed in cold PBS and lysed in 1% NP-
40, 20 mM Hepes, pH 7.9, 350 mM NaCl, 20% glycerol, 1 mM
MgCl
 
2
 
, 0.5 mM EDTA, 0.1 mM EGTA, 0.5 mM dithiothreitol,
containing 3 
 
m
 
g/ml aprotinin, 3 
 
m
 
g/ml leupeptin, and 2 mM
PMSF. Subsequently, proteins were separated under reducing
conditions on an SDS-polyacrylamide gel and electroblotted to a
polyvinylidene difluoride membrane (Amersham Buchler GmbH,
Braunschweig, Germany). Membranes were blocked for 1 h with
5% nonfat dry milk powder in TBS and then immunoblotted for
1 h with rabbit anti-PARP antibody (1:2,000; Boehringer Mann-
heim GmbH) and mouse mAbs directed against caspase-8 (1:10
dilution of a hybridoma supernatant; Biomedia, Baesweiler, Ger-
many) and caspase-3 (R&D Systems, Wiesbaden, Germany).
Membranes were washed four times with TBS/0.05% Tween 20
and incubated with the respective peroxidase-conjugated second-
ary antibody for 1 h. After extensive washing, the reaction was
developed by enhanced chemiluminescent staining using ECL re-
agents (Amersham Buchler GmbH).
 
Cytochrome c Release and In Vitro Caspase Activation.
 
For anal-
ysis of cytochrome c release, cells were collected by centrifuga-
tion, washed with ice-cold PBS, and resuspended in 5 vol of
buffer A containing 250 mM sucrose, 20 mM Hepes, pH 7.5, 1.5
mM MgCl
 
2
 
, 10 mM KCl, 1 mM EDTA, 1 mM EGTA, 1 mM
dithiothreitol, 0.1 mM PMSF, 10 
 
m
 
g/ml leupeptin, and 10 
 
m
 
g/ml
aprotinin. The cells were homogenized with 15 strokes in a
douncer, and the homogenates were centrifuged at 1,000 
 
g
 
 to
remove cell nuclei. The supernatants were transferred to a fresh
tube and centrifuged at 10,000 
 
g
 
 for 10 min to deplete mitochon-
dria. The resulting supernatants, designated as cytosolic S10 fraction,
from each sample were loaded on a 12%-SDS polyacrylamide gel.
Cytochrome c release was analyzed by immunoblotting with the
mouse mAb 7H8.2C12 (PharMingen Europe, Hamburg, Ger-
many). To evaluate the ability of cytochrome c to activate
caspases in cytosolic extracts, 150 
 
m
 
g of an S10 fraction was incu-
bated with 1.25 
 
m
 
M bovine cytochrome c (Sigma) and 1 mM
dATP at 30
 
8
 
C in a final volume of 25 
 
m
 
l for the indicated time
periods. At the end of the incubation, the reaction mixture was
loaded on an SDS-polyacrylamide gel and analyzed for caspase-3
and -8 cleavage as described above.
 
Measurement of Apoptosis.
 
For determination of apoptosis, 3 
 
3
 
10
 
4
 
 cells per well were seeded in microtiter plates and treated for
the indicated time points with anti-CD95 or the chemotherapeu-
tic agents. Leakage of fragmented DNA from apoptotic nuclei
was measured as described previously (27). In brief, apoptotic nu-
clei were prepared by lysing cells in a hypotonic buffer (1% so-
dium citrate, 0.1% Triton X-100, 50 
 
m
 
g/ml propidium iodide)
and subsequently analyzed by flow cytometry. Nuclei to the left
of the 2N peak containing hypodiploid DNA were considered as
apoptotic. In addition, cell death was determined by propidium
uptake into cells. All flow cytometry analyses were performed on
a FACScalibur
 
Ò
 
 (Becton Dickinson GmbH, Heidelberg, Ger-
many) using CellQuest analysis software.
 
Measurement of Intracellular ATP.
 
The cellular ATP content
was determined using a bioluminescence assay (Sigma). 10
 
6
 
 cells
were treated with the proapoptotic stimuli in the presence and
absence of oligomycin. After the indicated times, cells were
washed with PBS, lysed in 0.5% Triton X-100, 10 mM Tris- 
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HCl, pH 7.5, 1 mM EDTA and incubated for 10 min on ice. Af-
ter removal of cell debris, ATP content was measured with a lu-
ciferin/luciferase assay using a luminometer (model ML2200;
Dynatech Deutschland GmbH, Denkendorf, Germany). The
ATP content was calculated using an internal standard, and the
data were calculated as the mean from three experiments.
 
Results and Discussion
 
Caspase-8 has been identified as the most proximal
caspase which is recruited to the DISC by its unique DED
(7–9). In most cells, caspase-8 is synthesized as two iso-
forms of 
 
z
 
55 kD (caspase-8/a and -8/b) which, after for-
mation of intermediate cleavage products of 43 and 41 kD,
are processed to a p18 and p10 heterodimer (28, 29). As as-
sessed with an anti-p18 antibody, treatment of Jurkat T
lymphocytes with agonistic anti-CD95 antibody resulted in
the cleavage of procaspase-8 into its characteristic interme-
diate fragments and the active p18 subunit (Fig. 1). Inter-
estingly, an identical cleavage pattern was obtained after
treatment with other apoptotic stimuli, including the pro-
tein kinase inhibitor staurosporine, the anticancer drugs
doxorubicin and mitomycin C, and cycloheximide, an in-
hibitor of the protein synthesis (Fig. 1). Because apoptosis
mediated by anticancer drugs has been proposed to induce
the expression of CD95L and elicit cell death by subse-
quent CD95 interaction (20, 21), we also used the sub-
clone Jurkat-R, which was selected for resistance to CD95
signaling. Incubation with staurosporine, anticancer drugs,
and cycloheximide induced caspase-8 cleavage to a similar
extent in CD95-resistant and -sensitive cells, whereas vir-
tually no cleavage was observed by anti-CD95 in the
CD95-resistant Jurkat-R cell line (Fig. 1). Additional ex-
periments revealed that anticancer drugs induced caspase-8
activation with similar kinetics and dose dependency in
both cell types (data not shown). Therefore, these results
suggest that caspase-8 activation is not restricted to apoptosis
mediated by death receptors, but is also induced by other
proapoptotic stimuli in a CD95-independent pathway.
It has been suggested that the cellular energy charge acts
as control point of cell death by either necrosis or apopto-
sis, and that ATP is necessary for the execution of the apop-
totic program (25, 26, 30). In conjunction with cyto-
chrome c, ATP is required for the function of Apaf-1,
which initiates caspase activation in the mitochondria-con-
trolled pathway (12, 13, 15). Therefore, we investigated
whether manipulation of intracellular ATP levels can be used
to analyze the involvement of the cytochrome c/Apaf-1
pathway during apoptosis triggered by certain stimuli. ATP
levels were depleted in Jurkat cells by incubating cells in
glucose-free medium and oligomycin, an inhibitor of mito-
chondrial F
 
0
 
F
 
1
 
-ATPases. Under these conditions, ATP lev-
els declined rapidly within 60 min. Treatment of Jurkat cells
with anti-CD95 induced a marked cleavage of caspase-8
within 1 h that was not affected upon depletion of ATP by
oligomycin (Fig. 2 
 
A
 
). Furthermore, activation of caspase-3
was observed with slightly delayed kinetics in both ATP-
depleted and nondepleted cells. We also analyzed the
cleavage of PARP, an enzyme involved in DNA repair,
which has been shown to serve as a substrate for caspase-3
(31). Fig. 2 demonstrates that PARP, a 116-kD protein,
was cleaved into its characteristic 89-kD fragment with
similar kinetics as caspase-3, regardless of the presence or
absence of ATP.
Figure 1. Various apoptotic
stimuli induce caspase-8 activa-
tion independently of the CD95
pathway. 106 CD95-sensitive Jur-
kat or CD95-resistant Jurkat-R
cells were cultured in normal
growth medium and then either
left untreated (Control) or treated
with anti-CD95 (1 mg/ml, 3 h),
staurosporine (Stauro; 2.5 mM, 6
h), doxorubicin (Doxo; 2 mg/ml,
12 h), mitomycin C (Mito; 25 mg/ml, 8 h), or cycloheximide (CHX;
25 mg/ml, 6 h). Cellular proteins were separated by SDS-PAGE, and
proteolytic processing of caspase-8 was detected by immunoblotting with
an antibody against the caspase-8 p18 subunit. Open arrowheads, The two
isoforms of procaspase-8/a and -8/b, which are cleaved into the interme-
diate forms p43 and p41 (filled arrowheads) and finally processed to the ac-
tive p18 subunit (arrow).
Figure 2. ATP depletion differentially affects caspase activation and
cleavage of the caspase substrate PARP in response to anti-CD95 and
drug treatment. Jurkat cells were kept in glucose-free medium in either
the absence or presence of 2.5 mM oligomycin, and triggered with differ-
ent apoptotic stimuli. Anti-CD95 (A), staurosporine (B), doxorubicin
(C), and mitomycin C (D) were used at the drug concentrations described
in the legend to Fig. 1. Total cell lysates were subjected to 15% SDS-
PAGE to detect caspase-8 processing, and to 8–15% gradient SDS-PAGE
to detect cleavage of caspase-3 and PARP. Separated proteins were im-
munoblotted with caspase-8, caspase-3, and PARP-specific antibodies.
Top, Caspase-8 cleavage; only sections of the immunoblots indicating the
cleaved intermediate forms (p43 and p41) of caspase-8/a and -8/b are
shown. Middle, Processing of caspase-3; the immunoblots denote the po-
sition of procaspase-3 and its p17 active subunit. Bottom, PARP cleavage;
filled arrowheads indicate the uncleaved p116 and open arrowheads the
cleaved p89 form of PARP. 
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In contrast to the CD95 pathway, ATP depletion
strongly inhibited caspase-8 and -3 activation as well as
PARP cleavage in response to the receptor-independent
apoptotic stimuli. After treatment with staurosporine,
caspase-8 activation was detectable within 2 h and maximal
after 3 h. Inhibition of ATP production strongly prevented
caspase-8 activation (Fig. 2 
 
B
 
). Similar inhibitory effects
were obtained when caspase-3 and PARP cleavage were
analyzed. In addition to staurosporine, caspase activation in
response to chemotherapeutic drugs was almost completely
abolished in ATP-depleted cells. Doxorubicin-induced
caspase-8 activation started within 4–6 h, and was most
pronounced after 10 h (Fig. 2 
 
C
 
). Interestingly, similar to
CD95, caspase-3 activation and PARP cleavage followed
caspase-8 processing. However, in contrast to CD95, acti-
vation of both caspases was strongly abrogated by oligomy-
cin. Almost identical results were obtained during apoptosis
mediated by mitomycin C (Fig. 2 
 
D
 
) or etoposide (data not
shown). Therefore, the differential requirement of ATP for
caspase activation by either CD95 or chemotherapeutic
drugs indicates distinct regulatory pathways for the two
types of apoptosis.
Recent evidence has demonstrated that mitochondria
participate in the execution of apoptosis by release of cyto-
chrome c (10, 11, 17–19). Binding of cytochrome c to
Apaf-1 results in the cleavage of procaspase-9 or other
caspases, which in turn activate caspase-3 (13). Preparation
of cytosolic fractions confirmed that anti-CD95, staurospo-
rine, etoposide, and cycloheximide (Fig. 3 
 
A
 
), as well as the
other chemotherapeutic drugs (data not shown), induced
the redistribution of cytochrome c. It has been shown that
caspase-9 and -3 can be activated in cell-free systems upon
incubation of cytosolic fractions with cytochrome c and
dATP (12, 13, 15). Because caspase-8 activation so far has
been observed only after formation of an FADD-contain-
ing death receptor complex, we investigated whether
caspase-8 can be also activated in vitro by the addition of
cytochrome c. Indeed, incubation of cytosolic extracts with
cytochrome c resulted in a potent processing of caspase-8
that was even more pronounced than caspase-3 cleavage by
cytochrome c (Fig. 3 
 
B
 
). Therefore, the data demonstrate
that the initiator caspase-8 can be activated not only at the
DISC level but also by cytochrome c. Future studies will
show whether caspase-8 activation is mediated directly by
ATP and cytochrome c–bound Apaf-1 or by another prox-
imal caspase, such as caspase-9.
The above experiments suggested that drug-induced
caspase-8 activation is CD95-independent and entirely
controlled by an ATP-dependent step, most probably
Apaf-1 activation. Therefore, we investigated the effects of
ATP depletion on apoptotic DNA fragmentation and cell
death. Stimulation of Jurkat cells with anti-CD95 resulted
in the rapid formation of hypodiploid DNA, which was
comparable in ATP-depleted cells and cells kept under
normal growth conditions (Fig. 4 
 
A
 
). In contrast, stauro-
sporine-induced nuclear apoptosis was completely abro-
gated when ATP generation was inhibited (Fig. 4 
 
B
 
), con-
sistent with its effect on caspase activation. However, ATP
depletion did not prevent final cell death, as assessed by
membrane uptake of propidium iodide into cells. Instead,
in the presence of oligomycin, cell death occurred by ne-
crosis. Very similar effects of ATP depletion were found
Figure 3. Release of cytochrome c upon induction of apoptosis and in
vitro caspase activation. (A) Release of cytochrome c into the cytosol. Jur-
kat cells were either left untreated in normal culture medium or incu-
bated with anti-CD95 (1 mg/ml, 3 h), staurosporine (Stauro; 2.5 mM, 6 h),
etoposide (Etop; 25 mg/ml, 6 h), or cycloheximide (CHX; 25 mg/ml, 5 h).
Cells were then homogenized, and the S10 fraction depleted of mito-
chondria was subjected to 12% SDS-PAGE. The release of cytochrome c
into the cytosol was determined by immunoblotting. (B) In vitro activa-
tion of caspases by cytochrome c. Aliquots of an S10 fraction (150 mg)
were incubated for the indicated time with 1.25 mM cytochrome c in the
presence of dATP. A control fraction was incubated for 6 h in the absence
of cytochrome c. Proteolytic processing of caspase-8 (left) and caspase-3
(right) was determined by immunoblotting.
Figure 4. Effects of ATP de-
pletion on CD95- and staurospo-
rine-induced apoptosis. Jurkat cells
were either left untreated (open
symbols) or pretreated for 45 min
with oligomycin (filled symbols)
and then incubated with anti-
CD95 (1 mg/ml), staurosporine
(2.5 mM), or medium control
(dashed line). (A) Formation of apop-
totic nuclei was determined by flow cytometry of hypodiploid DNA. (B)
Membrane damage was measured by the uptake of propidium iodide into
cells and flow cytometry. (C) Measurement of intracellular ATP. Extracts
of control cells and cells treated for 2 h with anti-CD95 or staurosporine
(Stauro) in the presence and absence of oligomycin were analyzed for
ATP content using a bioluminescence assay. Data represent the mean of
three experiments. 
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when nuclear apoptosis and cell death in response to che-
motherapeutic drugs were analyzed (data not shown). Fig.
4 
 
C
 
 demonstrates that treatment of cells with oligomycin
resulted in a strong decrease in ATP production. However,
anti-CD95 and staurosporine themselves only slightly af-
fected intracellular ATP levels in early stages of apoptosis.
In summary, manipulation of intracellular ATP levels is a
useful means by which to discriminate between the in-
volvement of distinct apoptotic pathways. Although ATP
may affect other events, such as chromatin condensation
(32), the requirement for ATP can be most likely attributed
to its stimulatory function on Apaf-1 in the mitochondrial
pathway. Our data reveal that caspase activation induced by
staurosporine and chemotherapeutic drugs is entirely medi-
ated by this signaling pathway and does not require CD95
interaction as previously proposed (20, 21). In contrast,
CD95 signaling, although it activates mitochondria (33,
34), can circumvent this evolutionary conserved pathway
in order to activate caspases. Whether this bypass holds true
for all cell types or whether it is dependent on the degree of
DISC formation (34) remains to be shown. Our findings
convincingly demonstrate that the cytochrome c/Apaf-1
pathway and receptor-triggered signaling events are not
necessarily linked to each other.
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